Susquehanna International Group
AVDL

Susquehanna International Group’s Avadel Pharmaceuticals AVDL Stock Holding History

Susquehanna International Group’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-61,690
Closed -$1.33M – 13142
2025
Q4 		$1.33M Sell
61,690
-178,191
-74% -$3.46M ﹤0.01% 6533
2025
Q3 		$3.66M Sell
239,881
-280,595
-54% -$3.65M ﹤0.01% 4617
2025
Q2 		$4.61M Buy
520,476
+240,599
+86% +$2.11M ﹤0.01% 4120
2025
Q1 		$2.19M Buy
279,877
+2,019
+0.7% +$16.9K ﹤0.01% 5319
2024
Q4 		$2.92M Buy
+277,858
New +$3.37M ﹤0.01% 4528
2024
Q3 		– Sell
-20,997
Closed -$320K – 11934
2024
Q2 		$295K Buy
+20,997
New +$342K ﹤0.01% 9482
2024
Q1 		– Sell
-123,425
Closed -$1.84M – 12139
2023
Q4 		$1.74M Buy
+123,425
New +$1.45M ﹤0.01% 5662
2023
Q3 		– Sell
-130,473
Closed -$1.75M – 11990
2023
Q2 		$2.15M Sell
130,473
-199,903
-61% -$2.6M ﹤0.01% 5004
2023
Q1 		$3.03M Buy
330,376
+169,466
+105% +$1.39M ﹤0.01% 4311
2022
Q4 		$1.15M Sell
160,910
-60,159
-27% -$422K ﹤0.01% 5862
2022
Q3 		$1.11M Buy
+221,069
New +$1.22M ﹤0.01% 6368
2022
Q2 		– Sell
-260,471
Closed -$1.07M – 12842
2022
Q1 		$1.78M Buy
260,471
+41,813
+19% +$287K ﹤0.01% 5731
2021
Q4 		$1.77M Sell
218,658
-171,056
-44% -$1.56M ﹤0.01% 5797
2021
Q3 		$3.82M Buy
389,714
+201,502
+107% +$1.59M ﹤0.01% 4449
2021
Q2 		$1.27M Buy
188,212
+73,336
+64% +$582K ﹤0.01% 7098
2021
Q1 		$1.04M Sell
114,876
-73,935
-39% -$598K ﹤0.01% 7638
2020
Q4 		$1.26M Sell
188,811
-32,026
-15% -$200K ﹤0.01% 6141
2020
Q3 		$1.11M Buy
+220,837
New +$1.61M ﹤0.01% 5844
2020
Q1 		– Sell
-293,914
Closed -$2.26M – 10200
2019
Q4 		$2.22M Buy
293,914
+101,175
+52% +$534K ﹤0.01% 4145
2019
Q3 		$802K Buy
192,739
+94,350
+96% +$236K ﹤0.01% 6184
2019
Q2 		$284K Buy
98,389
+71,328
+264% +$123K ﹤0.01% 8421
2019
Q1 		$39K Sell
27,061
-6,321
-19% -$14.3K ﹤0.01% 8511
2018
Q4 		$86K Sell
33,382
-3,007
-8% -$10.2K ﹤0.01% 8284
2018
Q3 		$160K Sell
36,389
-15,026
-29% -$81.1K ﹤0.01% 8373
2018
Q2 		$315K Sell
51,415
-258
-0.5% -$1.81K ﹤0.01% 7741
2018
Q1 		$377K Buy
51,673
+17,093
+49% +$150K ﹤0.01% 7203
2017
Q4 		$284K Buy
34,580
+23,458
+211% +$220K ﹤0.01% 7676
2017
Q3 		$117K Buy
+11,122
New +$106K ﹤0.01% 8299
2017
Q1 		– Sell
-13,272
Closed -$133K – 8909
2016
Q4 		$138K Sell
13,272
-5,528
-29% -$60.7K ﹤0.01% 8900
2016
Q3 		$233K Buy
18,800
+4,178
+29% +$54.6K ﹤0.01% 7334
2016
Q2 		$157K Sell
14,622
-207
-1% -$2.21K ﹤0.01% 7789
2016
Q1 		$164K Buy
+14,829
New +$147K ﹤0.01% 8140
2015
Q4 		– Sell
-35,103
Closed -$547K – 9392
2015
Q3 		$573K Sell
35,103
-91,671
-72% -$2.02M ﹤0.01% 6861
2015
Q2 		$2.69M Buy
+126,774
New +$2.27M ﹤0.01% 4074
2015
Q1 		– Sell
-46,556
Closed -$729K – 9389
2014
Q4 		$798K Buy
46,556
+32,757
+237% +$468K ﹤0.01% 6308
2014
Q3 		$197K Sell
13,799
-58,578
-81% -$842K ﹤0.01% 8696
2014
Q2 		$1.09M Buy
72,377
+16,536
+30% +$199K ﹤0.01% 5879
2014
Q1 		$748K Buy
55,841
+9,781
+21% +$105K ﹤0.01% 6037
2013
Q4 		$371K Buy
46,060
+5,086
+12% +$35.9K ﹤0.01% 7232
2013
Q3 		$269K Buy
40,974
+4,736
+13% +$29.1K ﹤0.01% 7368
2013
Q2 		$223K Buy
+36,238
New +$187K ﹤0.01% 7280

Other funds holding AVDL

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Susquehanna International Group's AVDL Position: Q1 2026 in Review

Susquehanna International Group sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 61,690 shares — an estimated $1.33M sold.

Susquehanna International Group first reported a position in AVDL in Q2 2013 and held it in 41 quarters. The position peaked at $4.61M in Q2 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

  • Susquehanna International Group reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Susquehanna International Group sold 61,690 Avadel Pharmaceuticals shares in Q1 2026, an estimated $1.33M.
  • Susquehanna International Group first reported a position in Avadel Pharmaceuticals in Q2 2013 and held it in 41 quarters.
  • Susquehanna International Group's Avadel Pharmaceuticals position peaked at $4.61M in Q2 2025.
  • 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.